1. Home
  2. LEGN vs BFAM Comparison

LEGN vs BFAM Comparison

Compare LEGN & BFAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEGN
  • BFAM
  • Stock Information
  • Founded
  • LEGN 2014
  • BFAM 1986
  • Country
  • LEGN United States
  • BFAM United States
  • Employees
  • LEGN N/A
  • BFAM N/A
  • Industry
  • LEGN Biotechnology: Pharmaceutical Preparations
  • BFAM Other Consumer Services
  • Sector
  • LEGN Health Care
  • BFAM Consumer Discretionary
  • Exchange
  • LEGN Nasdaq
  • BFAM Nasdaq
  • Market Cap
  • LEGN 7.0B
  • BFAM 6.9B
  • IPO Year
  • LEGN 2020
  • BFAM 1997
  • Fundamental
  • Price
  • LEGN $31.08
  • BFAM $121.44
  • Analyst Decision
  • LEGN Strong Buy
  • BFAM Buy
  • Analyst Count
  • LEGN 13
  • BFAM 8
  • Target Price
  • LEGN $79.42
  • BFAM $139.13
  • AVG Volume (30 Days)
  • LEGN 1.6M
  • BFAM 397.2K
  • Earning Date
  • LEGN 05-13-2025
  • BFAM 05-05-2025
  • Dividend Yield
  • LEGN N/A
  • BFAM N/A
  • EPS Growth
  • LEGN N/A
  • BFAM 93.82
  • EPS
  • LEGN N/A
  • BFAM 2.77
  • Revenue
  • LEGN $728,303,000.00
  • BFAM $2,728,831,000.00
  • Revenue This Year
  • LEGN $65.96
  • BFAM $9.60
  • Revenue Next Year
  • LEGN $52.55
  • BFAM $7.51
  • P/E Ratio
  • LEGN N/A
  • BFAM $44.10
  • Revenue Growth
  • LEGN 112.46
  • BFAM 9.71
  • 52 Week Low
  • LEGN $29.27
  • BFAM $100.59
  • 52 Week High
  • LEGN $60.87
  • BFAM $141.90
  • Technical
  • Relative Strength Index (RSI)
  • LEGN 39.41
  • BFAM 48.91
  • Support Level
  • LEGN $30.25
  • BFAM $120.54
  • Resistance Level
  • LEGN $33.30
  • BFAM $125.25
  • Average True Range (ATR)
  • LEGN 1.53
  • BFAM 3.07
  • MACD
  • LEGN -0.18
  • BFAM 0.07
  • Stochastic Oscillator
  • LEGN 26.21
  • BFAM 28.77

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

About BFAM Bright Horizons Family Solutions Inc.

Bright Horizons Family Solutions Inc provides education and care solutions designed to help employers support their employees in managing their work/life balance. The company has three business segments: full-service center-based child care, backup care, and educational advisory services. The vast majority of the company's revenue is generated by full-service center-based child care, which includes traditional center-based child care and early education services. Other services provided by the company include in-home child and elder care, tuition assistance, and education consulting. The company earns more than half of its revenue in North America.

Share on Social Networks: